Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2026-01-01 @ 3:04 PM
Study NCT ID:
NCT05039658
Status:
UNKNOWN
Last Update Posted:
2021-09-09
First Post:
2021-09-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-27
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-07-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-12-02
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-01
First Submit QC Date:
None
Study First Post Date:
2021-09-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-01
Last Update Post Date:
2021-09-09
Last Update Post Date Type:
ACTUAL